DGAP-News

Fresenius Medical Care AG & Co. KGaA reports strong start to the year 2016

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Quarterly /
Interim Statement
Fresenius Medical Care AG & Co. KGaA reports strong start to the year 2016

03.05.2016 / 07:21
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

May 3, 2016

INVESTOR
NEWS

First quarter 2016

/

Fresenius Medical Care reports strong start to the year 2016

- Group revenue increased +6%, strong net income growth of +9%

- North America: revenue +10%, significant increase of operating income
(EBIT) +28%

- Segments outside North America strongly influenced by currency

- Care Coordination with strong organic growth of +17%

- First quarter performance in line to achieve full year guidance

First quarter 2016 key figures:

Net revenue $4,205 million +6%
Operating income $540 million +7%
Net income attributable to shareholders
of Fresenius Medical Care AG & Co. KGaA $228 million +9%
Basic earnings per share $0.75 +8%

Rice Powell, Chief Executive Officer of Fresenius Medical Care stated: "We
had a strong start to the year. Our core dialysis service and products
business showed a very strong underlying growth globally. While our
businesses outside the United States were largely influenced by currency,
the North American market delivered a very satisfying result. In addition,
Care Coordination continues to show strong topline growth. We are investing
in our future growth in this area, but also expect the profitability to
improve again in the course of the year. We are on track to achieve our
full year guidance for 2016."

Revenue & Earnings
Net revenue for the company improved by 6% and reached $4,205 million (+9%
at constant currency), largely driven by strong Net Health Care revenue
growth of +10% in North America. Net Health Care revenue contributed a 7%
increase to $3,414 million, while product revenue grew 2% (6% at constant
currency) to $791 million. Solid organic growth rates of 7% for Net Health
Care as well as for the products business demonstrated a solid business
performance. The development was primarily driven by higher revenue per
treatment and more dialysis days.

Total operating income (EBIT) increased by 7% to $540 million (margin of
12.8%). This increase was driven by lower costs for Health Care supplies, a
favorable impact from higher volume with commercial payors and further
efficiency gains partially offset by higher personnel expense related to
dialysis services in the North America segment, unfavourable foreign